Evidence map›Paper›PMID 39326670›Full record

ArticleThe Journal of molecular diagnostics : JMD2024

Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer.

Daniel P Salem, Laura T Bortolin, Dan Gusenleitner, Jonian Grosha, Ibukunoluwapo O Zabroski, Kelly M Biette, Sanchari Banerjee, Christopher R Sedlak, Delaney M Byrne, Bilal F Hamzeh and 13 more

Abstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Daniel P SalemMercy BioAnalytics Inc., Waltham, Massachusetts.
Laura T BortolinMercy BioAnalytics Inc., Waltham, Massachusetts.
Dan GusenleitnerMercy BioAnalytics Inc., Waltham, Massachusetts.
Jonian GroshaMercy BioAnalytics Inc., Waltham, Massachusetts.
Ibukunoluwapo O ZabroskiMercy BioAnalytics Inc., Waltham, Massachusetts.
Kelly M BietteMercy BioAnalytics Inc., Waltham, Massachusetts.
Sanchari BanerjeeMercy BioAnalytics Inc., Waltham, Massachusetts.
Christopher R SedlakMercy BioAnalytics Inc., Waltham, Massachusetts.
Delaney M ByrneMercy BioAnalytics Inc., Waltham, Massachusetts.
Bilal F HamzehMercy BioAnalytics Inc., Waltham, Massachusetts.
MacKenzie S KingMercy BioAnalytics Inc., Waltham, Massachusetts.
Lauren T CuocoMercy BioAnalytics Inc., Waltham, Massachusetts.
Timothy Santos-HeimanMercy BioAnalytics Inc., Waltham, Massachusetts.
Gabrielle N BarcaskeyMercy BioAnalytics Inc., Waltham, Massachusetts.
Katherine S YangMercy BioAnalytics Inc., Waltham, Massachusetts.
Peter A DuffMercy BioAnalytics Inc., Waltham, Massachusetts.
Emily S Winn-DeenMercy BioAnalytics Inc., Waltham, Massachusetts. Electronic address: emily@mercybio.com.
Toumy GuettoucheMercy BioAnalytics Inc., Waltham, Massachusetts.
Dawn R MattoonMercy BioAnalytics Inc., Waltham, Massachusetts.
Eric K HuangMercy BioAnalytics Inc., Waltham, Massachusetts.
Randy W SchekmanDepartment of Molecular and Cell Biology, Li Ka Shing Center, University of California Berkeley, Berkeley, California.
Anthony D CouvillonMercy BioAnalytics Inc., Waltham, Massachusetts. Electronic address: anthony@mercybio.com.
Joseph C SedlakMercy BioAnalytics Inc., Waltham, Massachusetts.

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Detection of cancer early, when it is most treatable, remains a significant challenge because of the lack of diagnostic methods sufficiently sensitive to detect nascent tumors. Early-stage tumors are small relative to their tissue of origin, heterogeneous, and infrequently manifest in clinical symptoms. The detection of early-stage tumors is challenging given the lack of tumor-specific indicators (ie, protein biomarkers, circulating tumor DNA) to enable detection using a noninvasive diagnostic assay. To overcome these obstacles, we have developed a liquid biopsy assay that interrogates circulating extracellular vesicles (EVs) to detect tumor-specific biomarkers colocalized on the surface of individual EVs. We demonstrate the technical feasibility of this approach in human cancer cell line-derived EVs, where we show strong correlations between assay signal and cell line gene/protein expression for the ovarian cancer-associated biomarkers bone marrow stromal antigen-2, folate receptor-α, and mucin-1. Furthermore, we demonstrate that detecting distinct colocalized biomarkers on the surface of EVs significantly improves discrimination performance relative to single biomarker measurements. Using this approach, we observe promising discrimination of high-grade serous ovarian cancer versus benign ovarian masses and healthy women in a proof-of-concept clinical study.

Indexed as

Biomarkers, TumorEarly Detection of CancerExtracellular VesiclesCell Line, TumorFemaleFolate Receptor 1HumansLiquid BiopsyMucin-1NeoplasmsOvarian NeoplasmsBiomarkers, TumorFolate Receptor 1Mucin-1

Identifiers

PMID39326670
PMCPMC13169315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.